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Abstract
AIM
To systematically review the currently available litera-
ture concerning the application of biologic agents such 
as platelet-rich plasma (PRP) and stem cells to promote 
anterior cruciate ligament (ACL) healing.
METHODS
A systematic review of the literature was performed on 
the use of biologic agents (i.e. , PRP or stem cells) to 
favor ACL healing during reconstruction or repair. The 
following inclusion criteria for relevant articles were 
used: Clinical reports of any level of evidence, written 
in English language, on the use of PRP or stem cells 
during ACL reconstruction/repair. Exclusion criteria were 
articles written in other languages, reviews, or studies 
analyzing other applications of PRP/stem cells in knee 
surgery not related to promoting ACL healing.
RESULTS
The database search identified 394 records that were 
screened. A total of 23 studies were included in the 
final analysis: In one paper stem cells were applied 
for ACL healing, in one paper there was a concomitant 
application of PRP and stem cells, whereas in the remain-
ing 21 papers PRP was used. Based on the ACL injury 
pattern, two papers investigated biologic agents in ACL 
partial tears whereas 21 papers in ACL reconstruction. 
Looking at the quality of the available literature, 17 
out of 21 studies dealing with ACL reconstruction were 
randomized controlled trials. Both studies on ACL repair 
were case series.
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CONCLUSION
There is a paucity of clinical trials investigating the role 
of stem cells in promoting ACL healing both in case 
of partial and complete tears. The role of PRP is still 
controversial and the only advantage emerging from 
the literature is related to a better graft maturation over 
time, without documenting beneficial effects in terms of 
clinical outcome, bone-graft integration and prevention 
of bony tunnel enlargement.
Key words: Platelet-rich plasma; Growth factors; Stem 
cells; Anterior cruciate ligament reconstruction; Anterior 
cruciate ligament repair; Anterior cruciate ligament 
healing; Sports medicine; Regenerative medicine
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Core tip: There has been a growing interest in the past 
years on regenerative approaches to stimulate healing 
of musculo-skeletal tissues. The present systematic 
review focuses on the clinical application of biologic 
agents [platelet-rich plasma (PRP) and stem cells] to 
favor anterior cruciate ligament healing during proce-
dures of reconstruction or repair. We show that there 
is inconclusive evidence to support the use of biologic 
augmentations, also due to the paucity of trials currently 
available, especially concerning stem cells. Looking at 
PRP, positive findings in terms of promotion of graft 
maturation were documented, but no beneficial influence 
was observed in terms of clinical outcome, bone-graft 
integration and prevention of tunnel enlargement.
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INTRODUCTION
Anterior cruciate ligament (ACL) injuries are among 
the most common conditions treated in everyday ortho­
paedic practice, with an increasing incidence in the past 
years due to a concurrent increase of sports activities 
among the general population[1,2]. ACL lesions can be 
distinguished in complete tears, generally treated by 
reconstruction, and partial tears (i.e., incomplete tears 
of one or both ACL bundles). Their management can be 
very challenging, ranging from non­operative treatment 
to surgery (augmentation or traditional reconstruction), 
depending on the patients’ symptoms and functional 
needs[3]. Epidemiological studies reveal an average 
incidence of 30 ACL injuries per 100000 people annually. 
Every year 175000 patients undergo ACL reconstruction 
in the United States[4]. These numbers highlight the social 
and economical impact of ACL injuries, and therefore 
justify the large interest in optimizing the treatment 
strategies for this particular injury. Several reconstructive 
techniques have been proposed in the past decades, 
mainly differing in terms of graft selection and graft 
fixation. The overall results are quite satisfactory, even 
at long­term evaluation, without a difference in terms of 
outcome among different surgical techniques[5,6]. Never­
theless, a documented failure rate of up to 14% for 
ACL reconstruction[7], stimulates scientific efforts to find 
solutions that could promote better graft maturation and 
healing to minimize the risk of failure and to allow a faster 
recovery for patients. Beyond maximizing the results 
of ACL reconstruction, there is an increasing demand 
for minimally invasive options to enhance intrinsic 
ACL healing in case of partial ruptures. These injuries 
represent a substantial amount of ACL injuries, whose 
treatment algorithm is still controversial. The possibility 
of promoting ACL healing without reconstruction is 
regarded as an attractive perspective, due to the inherent 
lower surgical morbidity and the faster return to physical 
activities. 
The recent progress in the field of regenerative 
medicine has led to the application of biologic agents 
(platelet­derived growth factors and stem cells), which 
could provide a positive stimulus to tissue healing. Platelet­
rich plasma (PRP) is currently the most exploited biological 
augmentation used in orthopaedic practice, both for the 
treatment of degenerative disease (like osteoarthritis 
and tendinopathies), and sports­related injuries[8,9]. It is 
an autologous blood derived product which is obtained 
by centrifugation or filtration of peripheral blood in order 
to concentrate platelets, which are a reservoir of several 
growth factors and bioactive molecules involved in tissue 
homeostasis and anabolism[10,11]. Several in vitro and 
animal studies demonstrated that intra­ligamentary 
administration of PRP determines an increase in cellular 
density and neovascularization of the ACL. This results 
in a better organization of collagen fibers for superior 
tensile resistance and biomechanical properties[12­14]. In 
light of these promising pre­clinical data, and also due 
to the easy preparation modalities, platelet­rich products 
are used more and more by clinicians from all over the 
world. In more recent times, mesenchymal stem cells 
from different sources have been proposed to augment 
ACL reconstruction or repair. In this case, flourishing pre-
clinical literature suggests that stem cell administration 
could stimulate tissue maturation, improve histological 
appearance, and favor bone­to­tendon integration[15,16]. 
Therefore, the implementation of experimental techniques 
in the clinical practice seems reasonable. A relevant number 
of clinical reports have been published investigating the 
actions of these fashionable biological strategies so far. 
The aim of the present paper is to systematically review 
the available literature concerning the application of 
PRP or stem cells to stimulate ACL healing, and to trace 
the state of the art in the use of biologic agents in this 
particular field of sports medicine. Moreover, this paper 
reveals if these novel strategies could really play a 
beneficial role in promoting graft maturation and healing 
and provide a better clinical outcome in the treatment of 
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complete and partial ACL lesions. 
MATERIALS AND METHODS
A systematic review of the literature was performed 
on the use of biologic agents (i.e., PRP or stem cells) 
to promote ACL healing during surgical reconstruction 
or repair. The search was conducted on the PubMed 
database on March 31, 2016 using the following formula: 
[(PRP or platelet concentrate or platelet gel or platelet 
rich plasma or ACP or autologous conditioned plasma or 
PRGF or PRF or platelet lysate or platelet derived growth 
factors or plasma growth factors or platelet rich fibrin) 
or (stem cell or mesenchymal or mesenchymal stem cell 
or bone marrow concentrate or bone marrow aspirate 
or adipose derived or peripheral blood)] and (ACL or 
anterior cruciate ligament).
Screening process and analysis were conducted 
separately by two independent observers (Di Matteo 
B and Andriolo L). First, the articles were screened by 
title and abstract. The following inclusion criteria for 
relevant articles were used during the initial screening 
of titles and abstracts: Clinical reports of any level of 
evidence, written in English language, published in the 
past 20 years (1996­2016), on the use of PRP or stem 
cells during ACL reconstruction/repair. Exclusion criteria 
were articles written in other languages, reviews, or 
studies analyzing other applications of PRP/stem cells 
in knee surgery not related to promoting ACL healing. 
In the second step, the full texts of the selected articles 
were screened, with further exclusions according to the 
previously described criteria. Moreover, the articles not 
reporting clinical, magnetic resonance imaging (MRI), or 
histologic results were excluded. Reference lists from the 
selected papers were also screened. A flowchart of the 
systematic review is provided in Figure 1. Relevant data 
were then extracted and collected in a unique database, 
with the consensus of the two observers, to be analyzed 
for the purposes of the present manuscript.
RESULTS
Qualitative synthesis of trials included in the review
The database search identified 394 records, and the 
abstracts were screened and selected according to the 
inclusion/exclusion criteria. As shown in Figure 1, a total 
of 27 full-text articles were assessed for eligibility. Four 
articles did not fulfill the inclusion criteria and were further 
excluded, leading to a total of 23 studies included in 
the final analysis (Figure 1). Only one paper dealt with 
the application of stem cells for ACL healing[17], one 
paper investigated the concurrent action of PRP and stem 
cells[18], whereas the remaining 21 papers focused on 
PRP application solely (one in partial rupture and 20 
in ACL reconstruction)[19­39]. Based on the ACL injury 
pattern, two papers investigated biologic agents in 
ACL partial tears[18,19] whereas 21 papers in ACL recon­
struction[17,20­39].
Looking at the quality of the available literature, 17 
out of 21 studies dealing with ACL reconstruction were 
randomized controlled trials (RCTs) (Table 1), whereas 
only case series are available for ACL repair. 
Concerning delivery methods of biologic agents, 
several different strategies were tested by authors, 
sometimes in combination (Table 1): Simple intra-
articular injection, intra­ligamentary injection, local 
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   Preclinical study (1 paper)
   PRP applied to favor donor 
   site healing after patellar tendon 
   harvesting (3 papers)
Figure 1  PRISMA flowchart resuming the papers’ selection process. PRP: Platelet-rich plasma.
Di Matteo B et al . Biologic agents for ACL healing
595 September 18, 2016|Volume 7|Issue 9|WJO|www.wjgnet.com
application onto the surface of the tendon graft, local 
injection within the bony tunnels, multiple intra­tendinous 
depots, or even selective administration through a spongy 
membrane soaked in PRP and sutured around the graft.
The different application methods will be discussed 
separately according to the specific ACL treatment 
analyzed in the clinical trials, i.e., repair (2 studies) or 
reconstruction (21 studies). A detailed description of the 
trial features is presented in Table 1.  
Biologic agents in ACL repair
Two papers investigated the contribution of biologic 
agents applied to promote healing of ACL in case of 
partial rupture. The first one, a retrospective case series, 
was published by Seijas et al[19] in 2014. They analyzed 
a small cohort of 19 football players who were treated 
by arthroscopic intra­ligamentary injection of 4 mL of 
leukocyte­poor PRP, followed by a 6 mL intra­articular 
injection at the end of surgery. The results were pretty 
satisfactory and 16 out of 19 patients were able to 
return to previous sports activity level with stable knees 
(evaluated by KT­1000), and in particular patients with 
Tegner Score 10 achieved the fastest return to sports. 
In the prospective trial published by Centeno et al[18], 
ten patients in total were treated by fluoroscopic guided 
intra­ligamentary injection of PRP + platelet lysate + 
bone marrow derived stem cells (harvested from the iliac 
crest and concentrated in the operating room). Overall 
results were satisfactory, with seven out of ten patients 
presenting signs of ACL healing at MRI evaluation 
performed at average 3 mo from the procedure. This 
evidence suggested a potential clinical usefulness of this 
approach to be confirmed by a larger trial. 
Biologic agents in ACL reconstruction
Twenty­one papers[17,20­39] investigated the role of 
biologic agents during ACL reconstruction; only one 
paper dealt[17] with the use of bone marrow concentrate, 
whereas 19 focused on PRP. With regards to the graft 
used for reconstruction, in 14 trials authors employed 
hamstrings, in three patellar tendon, in two trials ACLs 
were either reconstructed with hamstrings or patellar 
tendon, and just one paper documented the use of allo­
graft. The papers published analyzed the following main 
outcomes after biologic agents administration (Table 
1): (1) clinical results evaluated by functional scores, 
objective measurements and time to return to sports; 
(2) bony tunnel enlargement over time [evaluated 
by computed tomography (CT)]; (3) ACL graft­bone 
interface integration (evaluated by MRI); and (4) ACL 
graft maturation/remodeling (evaluated by MRI).
Looking at clinical outcomes and functional scores, 
eight papers[20­27] analyzed this specific aspect, seven 
of which were RCTs. Overall results were controversial: 
The RCTs authored by Del Torto et al[21], Darabos et 
al[22] and Vogrin et al[23] showed significant advantage of 
PRP administration over the control group. In particular, 
Del Torto et al[21] documented superior clinical outcome 
(IKDC subjective score) for the PRP group at any follow­
up evaluation up to 24 mo; similar results were reported 
by Darabos et al[22], who documented less swelling and 
better performance in functional tests at 6 mo, and also 
a significant difference in WOMAC Stiffness subscale at 
12 mo. Interestingly, also a reduced synovial fluid con-
centration of IL­1b was found in the PRP group after 10 d 
from the procedure. Vogrin et al[23] reported a significant 
difference in favor of PRP when comparing KT­2000 
values at 3 and 6 mo after surgery. It was suggested 
that growth factors played a substantial role in enhancing 
knee stability. Conversely, four RCTs[24­27] were not able 
to document any clinical benefit from PRP administration. 
In particular the trial authored by Valentí Azcárate et 
al[24] included 150 patients divided into three treatment 
groups and evaluated up to 24 mo. Two different PRP 
formulations (PRGF and lab made PRP) were tested 
without demonstrating any clinical benefit over control 
groups, either in terms of objective or subjective mea­
surements, with the exception of swelling, which was 
observed to be less 24 h after surgery in the PRGF group 
compared to PRP and control groups.
The issue of prevention of bony tunnels enlargement 
was addressed in six trials, all of which were RCTs[22,25,28­31]. 
Only in two of them[22,28] it was demonstrated that PRP, 
injected locally into the tunnels[28] or intra­articularly[22], 
could prevent their enlargement over time. Conversely, 
four papers revealed no significant difference with regard 
to this specific outcome between treatment groups. 
Additionally, one paper[31] revealed that the only positive 
effect in preventing tunnel widening was achieved by 
implanting a bone plug into the tunnel.
Concerning the graft­bone tunnel integration, eight 
papers (six RCTs)[17,21,24,31­35] investigated this specific 
issue. In only two RCTs the use of PRP provided bene­
ficial effects in terms of better corticalization of the 
tunnel walls[32] or higher vascularization at the graft­bone 
interface[33], whereas in the remaining trials[17,21,24,31,34,35] 
no inter­group difference was observed over time. 
Among the papers reporting negative results for PRP in 
this specific parameter, there is also only one study[17] 
documenting the role of bone marrow concentrate, which 
was not able to provide beneficial effects.
Diverging results were reported when analyzing the 
graft maturation over time after ACL reconstruction. Eight 
papers in total (five RCTs)[27,31,33,34,36­39] assessed this specific 
parameter, and six of them (four RCTs) documented a 
positive influence of PRP administration[27,31,36­39], whereas 
just two papers (one RCT) failed to reveal any inter­
group difference[33,34]. In the vast majority of cases graft 
maturation was evaluated by imaging assessment, re­
vealing a helpful role of PRP in stimulating a faster and 
better MRI or CT appearance of the graft. Signal of the 
graft was more similar to the posterior cruciate ligament, 
which points out an overall positive modulation of the 
ligamentization process. One paper[39] reported also 
histologic evaluation of the grafts, which were biopsied 
during second look arthroscopies performed after a 
mean of 15 mo from primary ACL reconstruction. In 
the PRP group, the graft presented a significantly better 
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Ref. Study design Methods Results
Clinical results
+ Del Torto et al[21] Prospective 
comparative study 
(PRFM vs control) 
28 patients (14 vs 14)
ACL reconstruction with hamstring tendon graft fixed in 
the femoral tunnel through the RIGIDFIX system (DePuy) 
and in the tibial tunnel through the Bio-INTRAFIX 
system (DePuy)
PRFM was prepared using Cascade Medical Enterprises 
2 tube kit (Cascade Medical Enterprises, Wayne, NJ). 
PRFM clot was sutured in the proximal graft loop and 
it reaches the proximal tunnel once the graft is pulled 
in place. Distally, the PRFM clot was inserted between 
the four strands of the G-ST graft before the interference 
screw system was applied
PRFM-augmented patients showed a statistically 
significant higher clinical improvement at 24 mo 
follow-up (P = 0.032)
Objective clinical evaluation both through IKDC 
score and with Rolimeter arthromether did not 
show any difference between the two groups
Magnussen et al[20] Retrospective 
comparative study 
(PRP vs control)
58 patients (29 vs 29)
ACL reconstruction with allograft tibial tendon, fixed 
with absorbable cross pin in femoral tunnel and 
absorbable interference screw in tibial tunnel
After graft positioning, intra-articular portion was coated 
with PRP prepared with GPS Ⅱ Platelet Concentrate 
Separation Kit (Biomet)
Decreased effusions at 10 ± 4 d was noted in the 
PRP group, but this difference disappeared by 8 
± 4 wk
No differences in patient-reported outcomes 
were noted in the 58 patients with two-year 
outcome data
Darabos et al[22] Randomized trial (ACS 
vs control) 
62 patients (31 vs 31)
ACL reconstruction with hamstring (30) or patellar 
tendon (32), fixed with BioTransFix (Arthrex) or RigidFix 
(Mytek) at femoral side, and with an interference screw 
at the tibial side
ACS was produced drawing venous blood into syringes 
containing pre-treated glass beads, and after a period of 
incubation serum is extracted through centrifugation. 
ACS was administered with an injection regime of 4 
injections on day 0 (day of surgery), day 1, day 6, and 
day 10
Clinical outcomes were consistently better in 
patients treated with ACS at all data points and 
for all outcome parameters, with statistically 
significant differences in the WOMAC stiffness 
subscale after 1 yr
Decrease in IL-1b synovial fluid concentration 
was more pronounced in ACS group, with 
statistically significant lower values in the ACS 
group at day 10
Vogrin et al[23] Randomized trial (PRP 
vs control)
45 patients (22 vs 23)
ACL reconstruction with double-looped semitendinosus 
and gracilis tendon graft fixed with two bioabsorbable 
cross pins in the femoral tunnel and one bioabsorbable 
interference screw in the tibial tunnel
PRP was produced with Magellan system (Medtronic) 
and applied into the femoral and tibial tunnels as well as 
onto the graft itself
PRP group demonstrated significantly better 
anteroposterior knee stability than control 
group: Calculated improvements in knee 
stability at 6 mo were 1.3 ± 1.8 mm in the control 
group and 3.1 ± 2.5 mm in the platelet gel group 
(P = 0.011)
- Valentí Azcárate 
et al[24]
Randomized trial (PRP 
vs PRGF vs control) 
150 patients (50 vs 50 vs 
50)
ACL reconstruction using a patellar tendon allograft 
transtibial technique fixed with a RigidFix technique 
(DePuy Mitek,) with two biodegradable cross pins at 
the femoral bone and a tibial biodegradable (Byocril) 
interference screw
PRP was produced with a double-spin procedure using 
a standard centrifuge and applied covering the ligament 
and suturing it over itself with gel in its interior, and 
introducing the gel obtained after activating the poor 
platelet concentration after implantation of the graft 
inside the tibial tunnel
PRP was produced following Anitua’s technique (PRGF-
Endoret Technology) and applied injecting it into the 
graft before implantation, with the biocompatible fibrin 
applied into the tibial tunnel at the end of surgery
No significant differences in functional results at 
the final follow-up of 24 m
No statistically significant differences between 
the three groups in CRP 1 and VAS 24 h after 
surgery
No significant differences in the range of knee 
motion, muscle torque, KT-1000 or IKDC score
The PRGF group showed a statistically significant 
improvement in swelling scores 24 h after surgery 
compared with the PRP and control groups
Vadalà et al[25] Randomized trial (PRP 
vs control)
40 patients (20 vs 20)
ACL reconstruction with hamstrings (Out-In technique), 
fixed with Swing-Bridge device on femoral side and 
Evolgate screw on tibial side
PRP was produced with Fast Biotech kit (MyCells PPT-
Platelet Preparation Tube) and applied as follows: 5 mL 
between peripheral part of the graft and the femoral 
tunnel wall; 5 mL in semisolid pattern above the graft; 5 
mL of liquid and semisolid PRP on the tibial side
Physical examination as well as the evaluation 
scales used showed no differences between the 
two groups at 14.7 mo of follow-up
Nin et al[26] Randomized trial (PRP 
vs control)
100 patients (50 vs 50)
ACL reconstruction with patellar tendon allograft, fixed 
with two biodegra-dable cross pins in femur and a tibial 
biodegradable interference screw
Ligament was covered with PRP (produced with 
standard centrifuge) and sutured over itself with PRP 
in its interior. The rest of the gel was introduced after 
implantation of the graft inside the tibial tunnel
The results did not show any statistically 
significant differences between the groups for 
inflammatory parameters, magnetic resonance 
imaging appearance of the graft, and clinical 
evaluation scores after 18 mo
Table 1  Synopsis of all clinical trials dealing with the application of biologic agents to promote anterior cruciate ligament healing
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 Ventura et al[27] Randomized trial (PRP 
vs control)
20 patients (10 vs 10)
ACL reconstruction with quadruple hamstring tendon 
graft, with a femoral transcondylic fixation (BioTransFix) 
and tibial interference screw (BioRCI, Smith and 
Nephew)
PRP was obtained according to the GPS Biomet-Merck 
technique (Biomet) and applied in femoral and tibial 
tunnels
There were no significant differences concerning 
clinical score and examination between the two 
groups 6 mo after ACL surgery
Tunnel enlargement
+ Starantzis et al[28] Randomized trial (PRP 
vs control)
51 patients (25 vs 26)
ACL reconstruction with hamstring tendons 
(Semitendinosus and Gracilis) as a quadrupled graft, 
using distal fixation in the femur (Crosspin Linvatec 
or Endobutton Linvatec) and tibial fixation with a 
biodegradable interference screw (Linvatec) plus bone 
bridge suture anchoring
Half of the PRP (produced using the Biomet GPS Ⅲ kit) 
was added between the strands of the graft and left to 
form a clot before the graft fixation. Then, the remaining 
3 mL was injected into the femoral tunnel using an 
introducer
The morphology of the dilated tunnels was 
conical in both groups 
There was a statistical significant difference in 
the mid distance of the tunnels between the two 
groups 1 yr after surgery
No significant difference of the Lysholm scores 
between the two groups during the observation 
period was detected
Darabos et al[22] Randomized trial (ACS 
vs control)
62 patients (31 vs 31)
ACL reconstruction with hamstring (30) or patellar 
tendon (32), fixed with BioTransFix (Arthrex) or RigidFix 
(Mytek) at femoral side, and with an interference screw 
at the tibial side
ACS was produced drawing venous blood into syringes 
containing pre-treated glass beads, and after a period of 
incubation serum was extracted through centrifugation. 
ACS was administered with an injection regime of four 
injections on day 0 (day of surgery), day 1, day 6, and 
day 10
Bone tunnel enlargement measured with CT 
scans was significantly less (6 mo: 8%, 12 mo: 
13%) in ACS group than in control group (6 mo: 
31%, 12 mo: 38%)
- Vadalà et al[25] Randomized trial (PRP 
vs control)
40 patients (20 vs 20)
ACL reconstruction with hamstrings (Out-In technique), 
fixed with Swing-Bridge device on femoral side and 
Evolgate screw on tibial side
PRP was produced with Fast Biotech kit (MyCells PPT-
Platelet Preparation Tube) and applied as follows: 5 mL 
between peripheral part of the graft and the femoral 
tunnel wall; 5 mL in semisolid pattern above the graft; 5 
mL of liquid and semisolid PRP on the tibial side
The use of PRP did not seem to be effective in 
preventing tunnel enlargement at 14.7 mo of 
follow-up
Mirzatolooei et 
al[29]
Randomized trial (PRP 
vs control)
46 patients (23 vs 23)
ACL reconstruction with single-bundle quadrupled 
autograft of hamstrings, fixed with a cross-pin in femoral 
tunnel and a bio-absorbable interference screw in tibial 
tunnel
Graft was immersed in the PRP solution (produced with 
Double syringe system, Arthrex) for five minutes before 
implantation; 2 mL of PRP was injected into the femoral 
tunnel and 1.5 mL into the tibial tunnel at the end of the 
surgery
Despite slightly less tunnel widening in the PRP 
group, there were no significant differences 
at any of the sites of measurement between 
immediately after surgery and three months 
post-operatively
Silva et al[30] Randomized trial (4 
groups)
40 patients (10 control 
vs 10 PRP in FT vs 10 
PRP in FT and intra-
articular at 2- and 4 
wk vs 10 PRP activated 
with thrombin in FT)
Double-bundle arthroscopic ACL reconstruction 
with autologous hamstring tendons, fixed with two 
Endobuttons for the AMT and PLT in the femur and two 
bioabsorbable interference screws in the tibia
PRP (produced with GPS Ⅲ Kit, Biomet) was placed 
between the strands of the graft in each femoral tunnel
At 3 mo postoperatively, all tunnels had 
enlarged compared to the diameter of the 
drill and most tunnels enlarged more in the 
midsection than at the aperture in a fusiform 
manner
The use of growth factors during and after 
surgery did not show any influence in the tunnel 
enlargement (P = 0.563)
Orrego et al[31] Randomized trial (4 
groups)
108 patients (27 control 
vs 26 PC vs 28 BP vs 27 
PC + BP)
ACL reconstructions with quadruple semitendinosus-
gracilis graft, fixed with a biodegradable transfixing 
pin proximally and a biodegradable inter-ference screw 
distally; BP was placed by interference fit at the femoral 
tunnel
Five milliliter PRP (produced with Biomet GPS Ⅱ kit, 
Biomet) was added between the graft strands before 
passing it into the tunnel. After fixation, 1 mL of PRP was 
injected into the femoral tunnel between the graft strands
The use of PC did not show any significant effect 
in the tunnel widening evolution at 6 mo follow-
up
The use of a BP effectively prevented tunnel 
widening
The BP and PC combination did not show 
a synergic effect as compared to PC or BP 
individually
ACL graft-bone interface/integration
+ Rupreht et al[32] Randomized trial (PRP 
vs control)
41 patients (21 vs 20)
ACL reconstruction with double-looped semitendinosus 
and gracilis tendon autograft, fixed with two 
bioabsorbable cross pins in femoral tunnel and one 
bioabsorbable interference screw in tibial tunnel.
PRP was applied after autograft positioning, into the 
femoral and tibial tunnels (1 mL in each of them), and 
onto the graft itself (3 mL)
A gradual increase in the percentage of the 
tunnel wall consisting of tunnel wall cortical 
bone (TCB) during the follow-up was observed. 
At 6 mo the mean percentage of TCB was 
significantly higher (P = 0.003) in the PRP group 
than in the control group
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Vogrin et al[33] Randomized trial (PRP 
vs control)
41 patients (21 vs 20)
ACL reconstruction with double-looped semitendinosus 
and gracilis tendon graft fixed with two bioabsorbable 
cross pins in the femoral tunnel and one bioabsorbable 
interference screw in the tibial tunnel
PRP was produced with Magellan system (Medtronic) 
and applied into the femoral and tibial tunnels as well as 
onto the graft itself
After 4-6 wk, there was a significantly higher 
level of vascularization in the osteoligamentous 
interface in PRP group (0.33 ± 0.09 vs 0.16 ± 0.09, 
P < 0.001)
In the intra-articular part of the graft, there was 
no evidence of revascularization in either group
- Del Torto et al[21] Prospective 
comparative study 
(PRFM vs control)
28 patients (14 vs 14)
ACL reconstruction with hamstring tendon graft fixed in 
the femoral tunnel through the RIGIDFIX system (DePuy) 
and in the tibial tunnel through the Bio-INTRAFIX 
system (DePuy)
PRFM was prepared using Cascade Medical Enterprises 
2 tube kit (Cascade Medical Enterprises). PRFM clot was 
sutured in the proximal graft loop and it reaches the 
proximal tunnel once the graft is pulled in place. Distally, 
the PRFM clot was inserted between the four strands of 
the G-ST graft before the interference screw system was 
applied
MRI evaluation considering graft–tunnel 
interface and graft signal intensity provided 
similar results between the two examined 
groups, without any statistically significant 
difference. In the majority of the cases, a good 
signal quality of the graft and a scarce film of 
synovial fluid at the graft–tunnel interface were 
observed
Silva et al[17] Randomized trial (BMC 
vs control)
43 patients (20 vs 23)
ACL reconstruction with double-looped semitendinosus 
and gracilis tendon autograft fixed with a Toggleloc 
Ziploop (Biomet) in femoral tunnel and a bioabsorbable 
interference screw (Biomet) in tibial tunnel
Bone marrow was harvested from the iliac crest and 
concentrated to obtain 3 mL BMC. 1.5 mL of BMC 
concentrate was injected inside the femoral end of the 
graft itself before graft positioning, and the remaining 
1.5 mL BMC injected within the tunnel around the graft, 
from the bottom down to the entrance of the tunnel
Adult non-cultivated BMC did not seem 
to accelerate graft-to-bone healing in ACL 
reconstruction: No difference in the signal-to-
noise ratio of the inter-zone on MRI between the 
experimental and the control group 3 mo after 
surgery
Valentí Azcárate 
et al[24]
Randomized trial (PRP 
vs PRGF vs control)
150 patients (50 vs 50 vs 
50)
ACL reconstruction using a patellar tendon allograft 
transtibial technique fixed with a RigidFix technique 
(DePuy Mitek) with two biodegradable cross pins at 
the femoral bone and a tibial biodegradable (Byocril) 
interference screw
PRP was produced with a double-spin procedure using 
a standard centrifuge and applied covering the ligament 
and suturing it over itself with gel in its interior, and 
introducing the gel obtained after activating the poor 
platelet concentration after implantation of the graft 
inside the tibial tunnel
PRP was produced following Anitua’s technique (PRGF-
Endoret Technology) and applied injecting it into the 
graft before implantation, with the biocompatible fibrin 
applied into the tibial tunnel at the end of surgery
No statistically significant differences were 
noted between groups in intensity, thickness, or 
uniformity of graft at 6 mo MRI
Figueroa et al[34] Comparative study 
(PRP vs control)
50 patients (30 vs 20)
ACL reconstruction with hamstring tendons fixed with 
a cross-pin in femoral tunnel and a bio-absorbable 
interference screw in tibial tunnel
PRP was produced with Magellan Magellan system 
(Medtronic) and applied under arthroscopy in both the 
tibial (3 mL) and femoral (3 mL) tunnels with a long 
needle syringe, and directly applied in the intra-articular 
graft portion (4 mL)
No statistically significant benefit in the PRP 
group in terms of integration assessment at 6 mo 
follow-up
Silva et al[35] Randomized trial (4 
groups)
40 patients (10 control 
vs 10 PRP in FT vs 10 
PRP in FT and intra-
articular at 2- and 4 
wk vs 10 PRP activated 
with thrombin in FT)
Double-bundle arthroscopic ACL reconstruction 
with autologous hamstring tendons, fixed with two 
Endobuttons for the AMT and PLT in the femur and two 
bioabsorbable interference screws in the tibia
PRP (produced with Mini GPS Ⅲ Kit, Biomet) was placed 
between the strands of the graft in each femoral tunnel
The graft integration was not complete at 3 mo 
after surgery in the PL and AM femoral tunnel, 
and the use of PRP isolated or with thrombin 
seemed not to accelerate tendon integration
Orrego et al[31] Randomized trial (4 
groups)
108 patients (27 control 
vs 26 PC vs 28 BP vs 27 
PC + BP)
ACL reconstructions with quadruple semitendinosus-
gracilis graft, fixed with a biodegradable transfixing 
pin proximally and a biodegradable interference screw 
distally; BP placed by interference fit at the femoral 
tunnel
5 mL PRP (produced with GPS Ⅱ kit, Biomet) was added 
between the graft strands before passing it into the 
tunnel. After fixation, 1 mL of PRP was injected into the 
femoral tunnel between the graft strands
The use of PC did not show any significant effect 
in the osteoligamentous interface at 6 mo follow-
up
ACL graft remodeling
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+ Seijas et al[36] Randomized trial (PRP 
vs control)
98 patients (49 vs 49)
ACL reconstruction with autologous patellar 
tendon grafts with 9 mm bone plugs and fixed with 
hydroxyapatite screws in femur and tibia
8 mL of PRP was produced with PRGF technique (BTI 
Systems Vitoria, Spain) and percutaneously injected into 
the suprapatellar joint after portal suture
More patients in the PRP group than controls 
attained higher stages of remodeling at month 4 
(P = 0.003), month 6 (P = 0.0001), and month 12 
(but NS P = 0.354)
Rupreht et al[37] Randomized trial (PRP 
vs control)
41 patients (21 vs 20)
ACL reconstruction with double-looped semitendinosus 
and gracilis tendon autograft, fixed with two 
bioabsorbable cross pins in femoral tunnel and one 
bioabsorbable interference screw in tibial tunnel
PRP was applied after autograft positioning, into the 
femoral and tibial tunnels (1 mL in each of them), and 
onto the graft itself (3 mL)
MRI measurements indicated a reduced extent 
of edema during the first postoperative month 
as well as an increased vascular density and 
microvessel permeability in the proximal tibial 
tunnel at 1 and 2.5 postoperative months as the 
effect of the application of PRP
Radice et al[38] Comparative study 
(PRP vs control)
50 patients (25 vs 25)
ACL reconstructions with BPTB autograft (15 vs 10) or 
Harmstring (10 vs 15). Fixation in BPTB autograft with 
metallic interference screws, in hamstring autograft 
with metallic or bioabsorbable cross-pin in the femur 
and a bioabsorbable screw with a metallic staple in the 
proximal tibia
PRP (produced with GPS Ⅲ Kit, Biomet) was 
administered with the help of a sutured and compressed 
Gelfoam; 5 mL PRP was added homogeneously so as to 
completely cover the graft
ACL reconstruction with the use of PRPG 
achieved complete homogeneous grafts assessed 
by MRI, in 179 d compared with 369 d for ACL 
reconstruction without PRPG. This represented 
a time shortening of 48% with respect to ACL 
reconstruction without PRPG
Sánchez et al[39] Comparative study 
(PRP vs control)
37 patients (22 vs 15)
ACL reconstruction with hamstring tendons, fixed with 
transcondylar screw proximally and PRGF-treated bone 
plug and two metal staples distally
6 mL PRP was produced with BTI System Ⅱ (BTI 
Biotechnology Institute) and injected within the tendon 
graft fascicles with several punctures performed along 
the graft length, graft soaked in PRP until implantation 
and the remaining aliquots applied at the portals during 
suturing
PRGF resulted in more mature tissue than 
controls at histology (P = 0.024)
Histologically evident newly formed connective 
tissue enveloping the graft was present in 77.3% 
of PRGF-treated grafts and 40% of controls
Overall, arthroscopic evaluations were not 
statistically different between PRGF and control 
groups (P = 0.051)
Orrego et al[31] Randomized trial (4 
groups)
108 patients (27 control 
vs 26 PC vs 28 BP vs 27 
PC + BP)
ACL reconstructions with quadruple semitendinosus-
gracilis graft, fixed with a biodegradable transfixing 
pin proximally and a biodegradable inter-ference screw 
distally; BP placed by interference fit at the femoral 
tunnel
5 mL PRP (produced with Biomet GPS Ⅱ kit, Biomet) 
was added between the graft strands before passing it 
into the tunnel. After fixation, 1 mL of PRP was injected 
into the femoral tunnel between the graft strands
The use of PC had an enhancing effect on the 
graft maturation process evaluated only by MRI 
signal intensity at 6 mo follow-up
Ventura et al[27] Randomized trial (PRP 
vs control)
20 patients (10 vs 10)
ACL reconstruction with quadruple hamstring tendon 
graft, with a femoral transcondylic fixation (BioTransFix, 
Arthrex) and tibial interference screw (BioRCI, Smith and 
Nephew)
PRP was obtained according to the GPS Biomet-Merck 
technique (Biomet) and applied in femoral and tibial 
tunnels
CT highlighted a significant difference (P < 0.01) 
between ACL density of the two groups and 
showed that ACL density was similar to that 
of the posterior cruciate ligament in GF-treated 
group at 6 mo follow-up
- Figueroa et al[34] Comparative study 
(PRP vs control)
50 patients (30 vs 20)
ACL reconstruction with hamstrings fixed with a femoral 
cross-pin and a tibial bio-absorbable interference screw
PRP was produced with Magellan Magellan system 
(Medtronic, Minneapolis, MN) and applied under 
arthroscopy in both the tibial (3 mL) and femoral (3 mL) 
tunnels with a long needle syringe, and directly applied 
in the intra-articular graft portion (4 mL)
No statistically significant benefit in the 
PRP group in terms of graft maturation 
(ligamentization) at 6 mo of follow-up
Vogrin et al[33] Randomized trial (PRP 
vs control)
41 patients (21 vs 20)
ACL reconstruction with double-looped semitendinosus 
and gracilis tendon graft fixed with two bioabsorbable 
cross pins in the femoral tunnel and one bioabsorbable 
interference screw in the tibial tunnel
PRP was produced with Magellan system (Medtronic, 
Minneapolis, MN) and applied into the femoral and tibial 
tunnels as well as onto the graft itself
After 4-6 wk, significantly higher level of 
vascularization in the osteoligamentous interface 
in PRP group (0.33 ± 0.09 vs 0.16 ± 0.09, P < 0.001).
No evidence of revascularization in the intra-
articular part in either group
ACL repair
+ Centeno et al[18] Prospective study 
(BMC, PRP, PL)
10 patients 
Pre-injection of hypertonic dextrose solution into the ACL 
using fluoroscopic guidance 2-5 d prior to BMC injection 
in order to prompt a brief inflammatory response in the 
ACL
Intra-ligamentous injection of autologous BMC 
(harvested from iliac crest and isolated through 
Patients included had ACL laxity on exam, and 
MRI evidence of grade 1, 2, or 3 ACL tears < 1 
cm retraction
7/10 patients showed improvement in objective 
measures of ACL integrity in their post-
procedure MRIs
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enveloping by mature connective tissue, with signs 
of improved graft maturation, depending on the time 
passed from surgery.
DISCUSSION
The main findings of the present systematic review are 
that: (1) there is a paucity of clinical trials investigating 
the role of stem cells in promoting ACL healing, both 
in the treatment of partial and complete ACL tears. 
Therefore, no conclusive statement can be issued re­
garding the efficacy of this treatment approach; (2) 
despite the high number of RCTs, the role of PRP in ACL 
healing is still controversial, and it is not possible to fully 
endorse this biologic strategy to this particular indication; 
and (3) the use of biologic agents in partial ACL rupture 
is very limited, with just two clinical trials published, and 
therefore, the possibility of treating this kind of injuries 
by regenerative approaches remains an open question.  
Biologic approaches to enhance healing of musculo­
skeletal injuries are for sure a fashionable topic in the 
field of regenerative medicine. The overall brilliant 
results documented by in vitro and in vivo trials have 
stimulated their use in clinical practice, with different 
indications and targets, ranging from degenerative 
conditions (such as osteoarthritis and tendinopathies) to 
muscle and ligament injuries[8,9]. The first product that 
has encountered a large clinical application (together 
with a large commercial success) is PRP, whose use 
has been documented in papers published more 
than a decade ago. Despite being no more a “novel” 
treatment option, there is still uncertainty about its real 
effectiveness and, up to the present moment, there is 
no clear recommendation for its use in any of the clinical 
conditions. Therefore, we underline the fact once again, 
that the positive findings from pre-clinical studies cannot 
be reproduced in the in vivo model, whose complexity 
cannot be fully mirrored in laboratory experiments[40]. 
Looking at PRP potential in ACL healing, the literature 
is not conclusive with regards to the benefit of PRP 
application in providing a faster recovery and better 
functional outcome after ACL reconstruction. However, 
the evidence is currently limited to short term evaluations 
(up to 24 mo), whereas no trial has yet pointed out if the 
administration of platelet­derived growth factors could 
be effective at longer follow­up, providing more stable 
results or lower rate of recurrent injury. Interestingly, 
most of the studies documented a superior graft matu­
ration over time after PRP administration. These findings 
were achieved by imaging evaluation, and in one case 
also by histology[39]. A better ligamentization of the graft 
may be related to superior and longer lasting mechanical 
properties that could impact clinical outcome at middle­
to­long term evaluation. In light of that, further studies 
correlating imaging, histology and functional scores are 
expected to better clarify the role of PRP. Considering that 
patients after ACL reconstruction have high expectations 
in terms of durability of results, the possibility of reducing 
re­injury rate and providing a more stable clinical outcome 
seems very attractive and could justify the use of biologic 
agents. With regards to aspects such as bone­graft 
integration and prevention of bony tunnel enlargement, 
results are controversial and, overall, the majority of 
trials fail to support the use of PRP for this indication. 
By the way, research is moving forward in the attempt 
to optimize PRP technology to obtain the best possible 
results[41]. The main limiting factor that scientists and 
clinicians have to overcome is the great inter­product 
variability and the absence of a well defined therapeutic 
protocol[42]. When so many variables come into play, 
there is an intrinsic difficulty in finding the right way to 
move on. First of all, there are plenty of different PRP 
products that could be used. All of them differ in many 
fundamental aspects, such as preparation procedures, 
cellular content, platelet concentration rate, physical 
properties and eventual use of activators to enhance 
growth factors’ release. Authors have been using either 
lab made products or commercial kits from several 
companies, all characterized by different preparation 
protocols that rendered different PRP formulations[11,43,44]. 
In particular, the aspect of cellularity is currently the 
most debated one and there are controversial findings 
regarding the role of the different components of PRP, 
especially leukocytes whose presence has been deemed 
as detrimental based on laboratory findings that have 
not been confirmed in the clinical setting, leaving many 
questions open to investigation[45,46]. 
Another fundamental issue regards the application 
modalities of PRP during ACL reconstruction or repair. 
Several different approaches have been proposed, 
ranging from simple intra­articular injections to intra­
ligamentary deposition, graft coating, topical use into 
centrifugation), PRP and PL (prepared from venous 
blood via centrifugation and recentrifugation after 
freezing) using fluoroscopic guidance. Remaining BMCs 
were injected into the joint
The mean VAS change was a decrease of 1.7 (P = 
0.25), the mean LEFS change was an increase of 
23.3 (P = 0.03), and mean reported improvement 
was 86.7%
Seijas et al[19] Retrospective study 
(PRGF-Endoret) 
19 patients
PRGF-Endoret was produced using the technique 
described by Anitua and applied with a spine needle in 
both the proximal origin of the bundle and in the middle 
portion thereof in an amount of about 4 cc
At the end of the surgery another injection of PRGF-
Endoret was administered (6 cc) in the articular space.
16/19 professional soccer players with partial 
ACL tears returned to the same level
Normal KT-1000 values in all operated cases
Time to return to play: 16.2 ± 1.4 wk for Tegner 
9 pts, 12.3 ± 1.1 for Tegner 10
PRP: Platelet rich plasma; ACL: Anterior cruciate ligament; PRFM: Platelet rich fibrin matrix; ACS: Autologous conditioned serum; PC: Platelet concentrate; 
BP: Bone plug; FT: Femoral tunnel; PLT: Posterolateral tunnel; AMT: Anteromedial tunnel; BPTB: Bone-patellar; PRGF: Plasma preparation rich in growth 
factors; BMC: Bone marrow concentrate; PL: Platelet lysate; VAS: Pain visual analog scale; NS: Non-significant; LEFS: Lower extremity functional scale.
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the bony tunnels, or at the bone­graft interface. Even 
more complex strategies, such as suturing PRP clots or 
PRP­soaked sponges directly onto the graft have been 
suggested. In any case, based on the available data, 
it is impossible to endorse an ideal product or an ideal 
therapeutic modality to stimulate ACL healing. 
Looking at the application of mesenchymal stem cells, 
they have been introduced into clinical practice more 
recently than PRP, and they have been tested mainly 
in the field of cartilage regeneration/osteoarthritis[47]. 
With regards to ACL healing, the current evidence is 
strongly affected by the paucity of literature available 
that prevents any indications for the use of such biolo­
gical augmentation. As pointed out previously, only two 
papers in total (one RCT and one case series) investi­
gated the potential efficacy of bone marrow concentrate 
in this particular field of sports medicine[17,18]. One of 
these studies applied the stem cell concentrate to treat 
partial ACL tears together with PRP, which prevents 
any clear understanding of the real contribution of each 
biological product. The lack of data is a severe flaw, 
also considering that stem cell therapy is characterized 
by the same great variability described in the case 
of PRP products. Many factors should be taken into 
account. First of all, the source of stem cells should 
be considered, since it is possible to obtain them from 
different anatomical sites (bone marrow, adipose tissue, 
synovial tissue, peripheral blood and so on), and this 
peculiar aspect could play a major role in determining 
clinical outcome. Furthermore, stem cells could be used 
as a concentrate, or could be expanded in vitro and then 
applied during surgery[48]. By the way, the application of 
cellular therapy in orthopaedics is under strict surveillance 
and clinicians have to face regulatory burdens that are 
currently limiting the number of ongoing clinical trials[49]. 
For this reason, there is such a great dichotomy between 
the flourishing pre-clinical literature and the very limited 
data coming from clinical studies. This explains the fact 
that mainly bone marrow concentrate has been tested 
for ACL healing at the moment, since it is the easiest 
and safest way to collect and administer stem cells in a 
surgical setting. In light of these remarks, both in the 
field of PRP and stem cell augmentation for ACL healing, 
there is a need of further basic science studies to better 
understand the mechanisms of action of these powerful 
biological agents. Moreover, there is also a need of more 
high­level comparative trials that could clarify if some 
specific “products” or applicative modalities are truly 
better than others. 
A further consideration should be issued on the 
ACL injury patterns that have been treated with bio­
logic agents. The large majority of papers (21) were 
focused on their application during ACL reconstructive 
surgery, whereas only two trials, both case series, have 
investigated their potential in partial ACL tears (Table 1). 
The possibility of enhancing ACL healing in case of partial 
rupture is very attractive, because it can contribute to 
functional recovery and avoid the higher surgical stress 
of traditional reconstruction. However, even in this case, 
the current lack of data prevents a reliable assessment 
of the efficacy of biologic agents, when applied for 
this specific purpose. The technique described in the 
literature to deliver PRP or stem cells into the injured 
ACL (intra­ligamentary injection under fluoroscopic or 
arthroscopic check) is feasible[18,19] and results seem to be 
encouraging. Again further high quality trials, with higher 
number of patients and longer follow­up, are needed 
to confirm these preliminary findings. Furthermore, 
considering that partial ACL tears may have variable 
features, it would also be clinically relevant to introduce 
and validate a classification system, with the aim of 
understanding whether the biological approach could be 
more effective in specific lesion patterns.
In conclusion, based on the available clinical evidence, 
there is a lack of data about the efficacy of stem cells 
in ACL healing, whereas the data concerning the role of 
PRP are not conclusive to understand if it could provide 
a faster recovery and better functional outcome during 
ACL repair/reconstruction. Despite some positive findings 
in terms of graft maturation and clinical outcome, further 
long­term studies are needed to identify whether the 
administration of PRP could truly play a beneficial role 
during ACL reconstruction. Lastly, in contrast to the large 
number of trials dealing with ACL reconstruction, the 
treatment of partial ACL tears with biologic agents has 
been poorly investigated, and therefore there is need 
of more high quality data to understand the efficacy of 
biologic agents in this particular application.
COMMENTS
Background
Complete and partial anterior cruciate ligament (ACL) tears are among the most 
common injuries treated by orthopaedic surgeons every day. Currently, there 
are several surgical approaches that have been proposed to reconstruct/repair 
torn ACL and, despite overall satisfactory clinical outcome at medium-long 
term, there is still a failure rate up to 14% as documented by some studies. The 
current trend of research is aimed at finding solutions that could provide better 
and longer lasting results by stimulating ligament regeneration through the use 
of powerful biologic agents, such as platelet-rich plasma (PRP) and stem cells. 
The main goal is to achieve a tissue quality which is more similar to the one of 
the native ligament. The aim of the present paper is to systematically review the 
state of art regarding the application of biologic agents to promote ACL healing.
Research frontiers
Tissue engineering and regenerative approaches are currently widely applied in 
orthopaedics to stimulate healing of several tissues, from bone to cartilage and 
ligaments. In particular, PRP and stem cells are the most exploited strategies 
tested in clinical practice. Their application in the field of ACL healing (both for 
reconstruction and repair) represents the current cutting-edge technology to 
stimulate ligament regeneration in the attempt to improve clinical outcomes. 
Innovations and breakthroughs
A total of 23 studies were included in the final analysis. In one paper stem cells 
were applied for ACL healing, in one paper there was a concomitant application 
of PRP and stem cells, whereas in the remaining 21 papers PRP was used. The 
main findings of the present systematic review are that: (1) there is a paucity of 
clinical trials investigating the role of stem cells in promoting ACL healing, both 
in the treatment of partial and complete ACL tears. Therefore, no conclusive 
indication can be issued regarding the efficacy of this treatment approach; (2) 
despite the high number of randomized controlled trials, the role of PRP in ACL 
healing is still controversial, and it is not possible to fully endorse this biologic 
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strategy to this particular indication; and (3) the use of biologic agents in partial 
ACL rupture is very limited, with only two clinical trials published, and therefore, 
the possibility of treating this kind of injuries by regenerative approaches 
remains an open question.   
Applications
The application of PRP and stem cells in the field of ACL repair/reconstruction is 
technically feasible and safe. Several different approaches have been proposed, 
ranging from simple intra-articular injections to intra-ligamentary deposition, graft 
coating, topic use into the bony tunnels, or at the bone-graft interface. Even more 
complex strategies, such as suturing PRP-clots or PRP-soaked sponges directly 
onto the graft have been suggested. However, at present moment, it is impossible 
to endorse an ideal biologic product or an ideal therapeutic modality to stimulate 
ACL healing. There is a need of further basic studies to better understand the 
mechanisms of action of these powerful biological agents and also more high-
level comparative trials are required to clarify if some specific “products” or 
applicative modalities are truly better than others. 
Terminology
PRP is an autologous blood derivative which contains a higher concentration 
of platelets with respect to whole blood. The platelets act as a resorvoir of a 
milieau of growth factors that could play a fundamental role in stimulating tissue 
healing and regeneration. Stem cells in orthopaedics are usually mesenchymal 
stem cells obtained from bone marrow. They can be concentrated or expanded 
in lab for being used as a biologic augmentation during surgical procedures or 
as an injective approach for treating a wide range of musculo-skeletal disorders.
Peer-review
This is a very interesting review article on biologic agents for ACL injury healing. It 
is well-written and has a correct methodology and structure.
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